Fuzzy,

With the information available right now for the three companies, I agree with you that BTI will likely be first out of the gate. All three have huge potential, but as KBC pointed out, BTI and RVX/Zenith have "completely different models for value and revenue." However, BTI's near term increase in valuation and share price is contigent on BTI producing those licensing deals that are required for this stock to move. Will Rob's statement of 2016 being a prosperous year come to fruition? We still have almost 5 months left to find out.

As KBC pointed out on the RVX board where you also posed this question, BTI has no clinical trials going right now and has no timeline disclosed to shareholders for going into trials. They may take their oncology program into trial(s) themselves, and have heard rumors of an imminent Phase 0 trial, but no details yet. Instead, BTI is primarily pursuing licensing deals with various pharmaceutical companies so that they may use Transcendpep (Mtfp) to get their drugs across the BBB. So these other companies will be conducting the clinical trials, not BTI. Importantly, for these other companies to run these trials, they need a licensing deal first. Many companies have been evaluating the Transcendpep technology for many months now, so bring on those licensing deal(s)!

BearDownAZ